Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial

A Case of Diabetic Ketoacidosis Following Chikungunya Virus Infection

“…5 There is no current treatment or vaccine for chikungunya; however, as this pathogen is rapidly emerging, efforts are being made to develop a vaccine. 2 Chang and other recently published a successful phase 1 clinical trial of a virus-like particle vaccine. 2 IgM antibody response to acute chikungunya virus infection is detectable between days 2 and 7 after the onset of fever with an enzyme-linked immunosorbent assay test.…”

“…1 There is no drug for treatment or vaccine for prevention available. 2 Chikungunya virus is an alphavirus of the Togaviridae family that is transmitted by mosquitoes of the genus Aedes (mainly Aedes aegypti and Aedes albopictus). 3 First isolated in 1952, chikungunya has reemerged in the past decade, causing widespread epidemics in [2005][2006] in the islands of the Indian Ocean and southern India.…”

Recent progress on chikungunya virus research

“…However, multiple doses of the VLP vaccine are often needed to induce protective neutralizing antibodies. Vaccination with a VLP vaccine, VRC-CHKVLP059-00-VP, stimulated significant neutralizing antibodies, and was demonstrated to be safe and well tolerated in phase I trials (Metz et al, 2013;Chang et al, 2014). This vaccine has progressed to phase II clinical trial.…”

Emerging alphaviruses in the Americas: Chikungunya and Mayaro

“…Some CHIKV vaccine candidates are currently under investigation. For example, a CHIKV particle-like vaccine has been investigated in a phase I clinical trial 49 . Recently, a vaccine candidate for MAYV that uses the internal ribosome entry site (IRES) of the encephalomyocarditis virus to replace the viral subgenomic promoter was able to change the host-specifi c mechanism of structural protein gene expression.…”